Ledyenska Ballesteros, PA
Medical · San Antonio, TXNPI 1114167962
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,836 of the $22,027 with a category attached, or 62.8%. Novo Nordisk accounts for 94.0% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $8,483, more than ten times the $206 reported in 2021. Among medical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 138 payments — averaging $159.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$21K
- Lilly USA, LLC$739
- Astellas Pharma US Inc$185
- Corcept Therapeutics$67
- Sunovion Pharmaceuticals Inc.$53
- Merck$50
- plus $224 from 8 others
What the payments were for
- Consulting fees$13,83663%
- Travel & lodging$4,48020%
- Food & beverage$3,54116%
- Education$1701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 70 | $20,709 |
| Lilly USA, LLC | 43 | $739 |
| Astellas Pharma US Inc | 3 | $185 |
| Corcept Therapeutics | 3 | $67 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Merck | 3 | $50 |
| AbbVie | 3 | $48 |
| Bayer | 2 | $38 |
| Lundbeck LLC | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Abbott | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$122
How this compares
$22,027 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 361 | $529,716 |
| OzempicSemaglutide | 301 | $352,456 |
| JardianceEmpagliflozin | 75 | $108,946 |
| LinzessLinaclotide | 61 | $45,939 |
| RybelsusSemaglutide | 27 | $36,071 |
| TrulicityDulaglutide | 13 | $34,031 |
| JanuviaSitagliptin Phosphate | 19 | $27,506 |
| MyrbetriqMirabegron | 29 | $26,559 |
| RexultiBrexpiprazole | 15 | $25,877 |
| VraylarCariprazine Hcl | 15 | $21,949 |
| GemtesaVibegron | 22 | $15,445 |
| FarxigaDapagliflozin Propanediol | 16 | $9,250 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $8,652 |
| BelsomraSuvorexant | 11 | $4,882 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $739 | $563,747374 claims |
| Novo NordiskOzempic, Rybelsus | $20,709 | $388,526328 claims |
| Boehringer IngelheimJardiance | $21 | $108,94675 claims |
| AbbVieLinzess, Vraylar | $48 | $67,88876 claims |
| MerckJanuvia, Belsomra | $50 | $32,38830 claims |
| Astellas Pharma US IncMyrbetriq | $185 | $26,55929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,490 medical providers in Texas.
Other medical in San Antonio
- Shakira CabreraSan Antonio$116K
- Courtney AldridgeSan Antonio$89K
- John KodoskySan Antonio$58K
- Amanda MillerSan Antonio$27K
- Felipe GalvanSan Antonio$26K
- Daniella ArellanoSan Antonio$15K
- Robert SchonhoffSan Antonio$14K
- Tanya GainesSan Antonio$14K
- Ivanna SaucedoSan Antonio$13K
- Mui LeeSan Antonio$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.